ExpreS2ion Biotechnologies is a world leading CRO biotech company

Our company has a proprietary and complete S2 recombinant protein technology base – ExpreS2, which was developed over ten years at Pharmexa A/S. We have in-depth practical experience with the non-viral Drosophila S2 expression technology for the production of recombinant proteins for preclinical development and for use in clinical trials.

Contribution to Malaria Vaccines/Research

By leveraging our ability to express malaria parasite proteins with ExpreS2 a cGMP-compatible system, we have enabled progress of malaria vaccine candidates into clinical research. ExpreS2ion Biotechnologies is working with top academic teams to advance vaccines directed at different malaria stages of infection: blood stage malaria and pregnancy malaria.


Services, Custom Proteins

“Challenging proteins made easy”

The ExpreS2 system, based on Drosophila S2 cell expression can solve your “protein dead-ends” by providing an alternative, cGMP-compatible expression system.
When to choose the S2 expression system:

  • Secreted or secretable proteins
  • Low/non-expressing proteins in HEK293 or BEVS
  • Issues with protein cleavage during production
  • Heterodimers or further multimeric proteins
  • If variable glycosylation is an issue
  • If you need a cGMP-compatible system

ExpreS2ion Biotechnologies specializes in establishment of high-producing cell lines together with upstream process development and working with customers to solve technical problems in molecular biology, protein expression or other issues relating to S2 cells. S2 related reagents are also available.


Latest news

February 2014 : ExpreS2ion Biotechnologies is mentioned in “Ingeniøren”. Follow the link to read the article (in Danish) Continue reading

October 2013 : ExpreS2ion Biotechnologies is a Nordic Star: selected by the hosts to Nordic Life Sciences Days, which took place in Stockholm, October 14-15... Continue reading

October 2013 : ExpreS2ion Biotechnologies is again sponsoring the 14th Annual World Vaccine Congress, taking place in France, October 16-17... Continue reading

  • The abstract from the poster presentation about "Development of a Drosophila S2 insect-cell based placental malaria vaccine production process" at the “23rd ESACT Meeting”. Read the abstract here

  • An article on the June 2013 issue of Pharmaceutical Bioprocessing reviews the applications of S2 cells in research and the clinic. Read the article here

  • ExpreS2 protein expression platform is licensed to Cancer Research UK’s Protein Purification Facility Read the PR here